miR-6884-5p在非小细胞肺癌中的表达及与肿瘤标志物的相关性

doi:10.3760/cma.j.cn441417-20240515-05013

摘要/Abstract

摘要：

目的　分析miR-6884-5p在非小细胞肺癌（NSCLC）中的表达，并探讨其与肿瘤标志物的相关性及预后价值。方法　收集2017年1月至2019年1月商丘市第一人民医院治疗的91例NSCLC患者样本。术中采集患者的癌组织及癌旁组织，同时收集50例正常人血清作为对照组。NSCLC患者：男55例，女36例，年龄（60.3±7.4）岁；正常对照组：男27例，女23例，年龄（60.1±5.7）岁。采用实时定量PCR（qRT-PCR）检测NSCLC患者肿瘤组织及血清中miR-6884-5p的相对表达水平。通过受试者操作特征曲线（ROC）分析miR-6884-5p在NSCLC诊断中的价值。采用Cox回归分析影响NSCLC患者5年生存的独立预后因素。统计学方法采用χ²检验和t检验。结果　肿瘤组织中miR-6884-5p的表达低于癌旁组织（P<0.001）；NSCLC患者血清中miR-6884-5p的表达低于正常对照组（P<0.001）。ROC分析显示，血清miR-6884-5p在NSCLC诊断中的曲线下面积为0.863。血清中miR-6884-5p的表达与癌抗原125（CA125）和癌胚抗原（CEA）均呈负相关（均P<0.05）。miR-6884-5p低表达组患者的临床高分期（III+IV）和淋巴结转移数均高于高表达组（均P<0.05），5年生存率低于高表达组（P<0.05）。多因素Cox回归分析发现，miR-6884-5p（HR=0.370，95%CI 0.206～0.664）、年龄（HR=2.639，95%CI 1.505～4.627）、肿瘤大小（HR=2.415，95%CI 1.392～4.190）、临床分期（HR=0.339，95%CI 0.193～0.597）、淋巴结转移（HR=3.058，95%CI 1.760～5.311）是影响患者5年生存的独立预后因素（均P<0.05）。结论　miR-6884-5p在NSCLC中低表达与肿瘤进展及不良预后密切相关，有望成为潜在的生物标志物和治疗靶点。

关键词:

非小细胞肺癌, miR-6884-5p, 肿瘤标志物, 预后

Abstract:

Objective　To analyze the expression of miR-6884-5p in non-small cell lung cancer (NSCLC) and its correlations with tumor markers and prognosis. Methods　Samples from 91 NSCLC patients treated in Shangqiu First People's Hospital from January 2017 to January 2019 were collected. Tumor tissues and adjacent non-tumor tissues were collected during surgery. Serum samples from 50 healthy individuals were collected as a control group. NSCLC patients : 55 males and 36 females, aged (60.3±7.4) years ; Control group : 27 males and 23 females, aged (60.1±5.7) years. The relative expression levels of miR-6884-5p in tumor tissues and serum were measured using quantitative real-time PCR (qRT-PCR). The diagnostic value of miR-6884-5p in NSCLC patients was assessed using the receiver operating characteristic curve (ROC). Cox regression analysis was used to identify independent prognostic factors affecting 5-year survival of NSCLC patients. Statistical methods were χ² test and t test. Results　The expression of miR-6884-5p in tumor tissues was lower than that in adjacent non-tumor tissues (P<0.001). The relative expression level of miR-6884-5p in the serum of NSCLC patients was lower than that of the control group (P<0.001). ROC analysis revealed that the area under the curve (AUC) for serum miR-6884-5p in diagnosing NSCLC was 0.863. Serum miR-6884-5p expression was negatively correlated with cancer antigen 125 (CA125) and carcinoembryonic antigen (CEA) levels (both P<0.05). The patients in the miR-6884-5p low expression group had a higher incidence of advanced clinical stages (III+IV) and lymph node metastasis compared to the high expression group (both P<0.01). The 5-year survival rate of the low expression group was lower than that of the high expression group (P<0.05). Multivariate Cox regression analysis showed that miR-6884-5p (HR=0.370, 95%CI 0.206-0.664), age (HR=2.639, 95%CI 1.505-4.627), tumor size (HR=2.415, 95%CI 1.392-4.190), clinical stage (HR=0.339, 95%CI 0.193-0.597), and lymph node metastasis (HR=3.058, 95%CI 1.760-5.311) were independent prognostic factors affecting 5-year survival (all P<0.05). Conclusion　The low expression of miR-6884-5p in NSCLC is closely associated with tumor progression and poor prognosis, suggesting that miR-6884-5p may serve as a potential biomarker and therapeutic target.

Key words:

Non-small cell lung cancer, miR-6884-5p, Tumor markers, Prognosis

刘珍珍刘谩贾永庆杨美菊.

miR-6884-5p在非小细胞肺癌中的表达及与肿瘤标志物的相关性 [J]. 国际医药卫生导报, 2025, 31(5): 766-770.

Liu Zhenzhen, Liu Man, Jia Yongqing, Yang Meiju.

Expression of miR-6884-5p in non-small cell lung cancer and its correlations with tumor markers [J]. International Medicine and Health Guidance News, 2025, 31(5): 766-770.

参考文献

[1] 鲁朝霞,马骥雄,马菊红,等. 2010-2019年甘肃省肿瘤登记地区肺癌发病的流行病学特征分析[J]. 中国肺癌杂志,2024,27(2):88-95. DOI:10.3779/j.issn.1009-3419.2024. 102.05.
[2] 尹明明. ProGRP、CYFRA21-1和胱抑素C联合检测对肺癌的诊断价值[J]. 罕少疾病杂志,2023,30(10):23-24. DOI:10.3969/j.issn.1009-3257.2023.10.010.
[3] 阿里甫·依马木,文智,周永,等. 高危人群低剂量CT与肿瘤标志物联合检查早期肺癌的效能研究[J]. 中国CT和MRI杂志,2024,22(2):58-60. DOI:10.3969/j.issn.1672- 5131.2024.02.018.
[4] 徐鹤,王伟,刘长林,等. 临床-影像组学列线图对非小细胞肺癌肺门与纵隔淋巴结转移的预测研究[J]. 中国CT和MRI杂志,2023,21(11):84-87. DOI:10.3969/j.issn.1672-5131. 2023.11.026.
[5] 林慧,陈佳菁,张冲冲,等. miR-934在乳腺癌组织中的表达及临床意义[J]. 罕少疾病杂志,2023,30(4):34-36. DOI:10.3969/j.issn.1009-3257.2023.04.015.
[6] 郝磊,卢柳西,李琼莉,等. 过表达miR-124-1基因的骨髓间充质干细胞外泌体调控小胶质细胞M2型极化对脑卒中的影响[J]. 陆军军医大学学报,2024,46(5):458-466. DOI:10.16016/j.2097-0927.202305003.
[7] 罗世程,肖冬平,黄秀玲,等. LncRNA-CASC2竞争性结合miR-193a-5p调控GSDMD焦亡通路逆转非小细胞肺癌顺铂耐药的分子机制[J]. 中国当代医药,2024,31(1):10-14. DOI:10.3969/j.issn.1674-4721.2024.01.004.
[8] 李静,李海洋,赵振山. miR-567对非小细胞肺癌细胞恶性生物学行为及吉非替尼耐药的影响[J]. 广西医科大学学报,2023,40(3):420-426. DOI:10.16190/j.cnki.45-1211/r.2023.03.012.
[9] Zhang L, Chi W, Wang X,et al. The role of miR-6884-5p in epithelial-mesenchymal transition in non-small cell lung cancer[J]. Aging (Albany NY), 2024,16(2):1968-1979. DOI: 10.18632/aging.205474.
[10] 王琳娜,王静. 血清外泌体miR-486-3p对非小细胞肺癌早期诊断价值[J]. 青岛大学学报(医学版),2023,59(2):292-295. DOI:10.11712/jms.2096-5532.2023.59.068.
[11] 冉晶晶,李彤,缪治永,等. 外泌体源性microRNAs在肺癌转移及早期诊断中的研究进展[J]. 生命科学,2021,33(6):759-765. DOI:10.13376/j.cbls/2021081.
[12] 郭天灏,周红光,李黎,等. miRNA与肺癌早期诊断及癌毒理论关系的研究进展[J]. 中国中医基础医学杂志,2019,25(12):1769-1772.
[13] 冯敏. 筛选血清外泌体来源的miRNAs作为非小细胞肺癌早期诊断及中药疗效评价的生物标志物[D]. 辽宁:大连医科大学,2018.
[14] 徐柯楠,刘静,夏丽,等. LINC_00355通过miR-15a-5p调节PHF19在肺癌侵袭转移中的作用机制研究[J]. 国际检验医学杂志,2024,45(5):629-634,640. DOI:10.3969/j.issn.1673-4130.2024.05.024.
[15] Cui S, Li F. RHPN1‑AS1 promotes ovarian carcinogenesis by sponging miR‑6884‑5p thus releasing TOP2A mRNA[J]. Oncol Rep, 2021,46(4):221.DOI: 10.3892/or.2021.8172.
[16] Tian H, Liang G, Qin Q,et al. Circ_0023990 promotes the proliferation, invasion, and glycolysis of esophageal squamous cell carcinoma cells via targeting miR-6884-5p/PAK1 axis[J]. Biochem Genet, 2024 ,62(5):3876-3892. DOI: 10.1007/s10528-024-10674-z.
[17] 陈艳,向敏,王熙才,等. 非小细胞肺癌患者外周血有核细胞miR-205-5p水平及其临床意义[J]. 中国肿瘤生物治疗杂志,2017,24(12):1414-1418. DOI:10.3872/j.issn.1007- 385x.2017.12.013.
[18] 刘文芳,何慧琴,操龙洋. 血清miR-19b、miR-9及miR-155-5P在早期食管鳞状细胞癌患者血清中的表达及临床意义[J]. 现代实用医学,2022,34(1):38-40,封3. DOI:10.3969/j.issn.1671-0800.2022.01.016.
[19] 李青黛,吴萌,王红兵. 非小细胞肺癌根治术后辅助化疗的预后因素分析[J]. 肿瘤药学,2023,13(1):99-105. DOI:10.3969/j.issn.2095-1264.2023.01.16.
[20] 段桦,罗楚凡,崔慧娟,等. 227例晚期非小细胞肺癌患者的预后因素分析[J]. 癌症进展,2020,18(4):366-370. DOI:10.11877/j.issn.1672-1535.2020.18.04.11.
[21] 潘剑云,黄贻恩,洪淑君,等.CYFRA21-1、CEA和Ki67在非小细胞肺癌中的表达及预后因素分析[J].中国胸心血管外科临床杂志,2024,31(5):682-688.